

RARE DISEASE DAY 2020 POLICY BRIEFING FROM PLEDGE TO ACTION



European Parliament, Brussels

Room 3H1

18Th of February, 10hoo – 11hoo





Our agenda for today

Welcome and opening

What are rare diseases? What is the network, rationale, main purpose

What topics will be working on? Where does EURORDIS have expertise in to offer?

How can you help concretely?

Q&A/Closing





WHAT ARE RARE DISEASES?

There are

6,000⁺ IDENTIFIED RARE DISEASES

Article 'Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database', European Journal of Human Genetics (2019)

#RareDiseaseDay 29 FEBRUARY 2020







72% GENETIC

whilst others are the result of **infections** (bacterial or viral), **allergies** and **environmental causes** or are **rare cancers**.

Article 'Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database', European Journal of Human Genetics (2019)

#RareDiseaseDay 29 FEBRUARY 2020







Start in CHILDHOOD

Article 'Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database', European Journal of Human Genetics (2019)

#RareDiseaseDay 29 FEBRUARY 2020







EURORDIS.ORG

MILLION PEOPLE WORLDWIDE Iving with a rare disease

Article 'Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database', European Journal of Human Genetics (2019)

#RareDiseaseDay 29 FEBRUARY 2020







Rare diseases currently affect **DOPULATION**

Article 'Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database', European Journal of Human Genetics (2019)

EURORDIS.ORG

#RareDiseaseDay 29 FEBRUARY 2020





Collectively the number of people living with a rare disease is equivalent to the population of the

WORLD'S **RD LARGEST COUNTRY**


300 million people worldwide are living with a rare disease








The EU added value (1): Pooling knowledge to improve diagnosis





The EU added value (2): partnership for research



EURORDIS.ORG



The EU added value (3): therapies development

Orphan medicines key figures

Since 2000

Removed from

Marketed, but no

longer "orphans"

the market



2216 Orphan designations

> 176 Authorised

> > OMPs

To date



209 Orphan designations

included in authorised indication

68 To be used in children

109

Products with a marketing authorisation and an orphan status in the European Union









Rare diseases seriously impact everyday life

7 in 10 & carers

reduced or stopped professional activity due to their or their family member's rare disease.

2/3 of carers

spend more than 2 hours a day on disease-related tasks.

* Rare Barometer Voices sample compared to International Social Survey Programme, 2011

EURORDIS.ORG



8 in 10 & carers

have difficulties completing daily tasks (household chores, preparing meals, shopping etc.)

3 times more people

living with a rare disease and carers report being unhappy and depressed than the general population*




An insight into the participation of rare disease patients in research



30 million people are living with a rare disease in Europe and 300 million worldwide

No cure for the vast majority of diseases and few treatments available 3213 rare disease patients and their families responded to the survey, conducted in 23 languages across 42 countries worldwide





together over 8,000 patients, carers and family members to make the voice of the rare disease community stronger. hank you to all Rare Barometer Voices participants and partners! To read the full report register to participate in future surveys or for more information, visit: eurordis.org/voices



Rare disease patients' experience of treatments

69% have already experienced a treatment

31% have never experienced any treatment




Only 5 % have already experienced a curative treatment

3% a treatment to prevent the disease

31% a treatment to slow down the disease

62% a symptomatic treatment









WHAT IS THE NETWORK?

Why a network of Parliamentary Advocates for Rare Diseases?

- European Union added-value of action on rare diseases
 - Need of action beyond national borders
- Breakthrough legislation driven mostly by the EU institutions & implemented at national level
 - Need for collaboration at EU level & between the EU and national level
- Create a pool of advocates amongst policy makers
 - ✓ Need to raise awareness amongst decision-makers
 - Strong signal of Parliamentarians commitment & relevance of rare diseases



Core missions of the Parliamentary Advocates for Rare Diseases

- 1. Explore and discuss specific challenges faced by people living with a rare disease
- 2. Shape political input for future legislation and programmes in a new framework for Rare Diseases
- Work to make rare diseases an integral part of EU, national and regional programmes in health, research, social affairs and other relevant policies



From Pledge to Action

2

ENABLES ALL PEOPLE LIVING WITH A RARE DISEASE TO RECEIVE AN ACCURATE DIAGNOSIS AND APPROPRIATE CARE WITHIN ONE YEAR OF COMING TO MEDICAL ATTENTION

SUPPORTS HOLISTIC CARE AND SOCIAL SYSTEMS That are inclusive of People living with a rare Disease, throughout Their lives (¥)

3

SEIZES OPPORTUNITIES IN Science and innovation That embody hope for People living with rare Diseases and their carers And can change their Lives

PEOPLE WITH RARE DISEASES AND THEIR REPRESENTATIVES MUST BE ENGAGED In All Fora where decisions that affect their lives are made.



On access to diagnosis and care

ENABLES ALL PEOPLE LIVING WITH A RARE DISEASE TO RECEIVE AN ACCURATE DIAGNOSIS AND APPROPRIATE CARE WITHIN ONE YEAR OF COMING TO MEDICAL ATTENTION

- 1. Reframe the current European strategy tacking rare diseases to adequately address the needs of the rare disease community
- Advancing the work that has been initiated during the previous legislature to support EU-wide coordination on HTA
- 3. Scrutinise activity on the implementation of the Directive on Patients' Rights in Cross-Border Healthcare in line with report of European Court of Auditors



Support holistic care



- 1. Ensure that in the MMF 2021 2027 and successive annual budget and related programme, adequate and streamlined funding is appropriated for activities of the European Reference Networks (ERNs)
- 2. Promote the implementation of the recommendations on ERN integration in national healthcare systems;
- 3. Ensure that measures to achieve holistic care for people living with rare diseases and their families, such as access to social services, disability assessment for rare diseases are streamlined in the upcoming European Disability Strategy



Foster research



- 1. Promote the importance of **fostering research in the area of rare cancers** in the context of the Commission's Beating Cancer Plan.
- Support the rare disease patient community in getting engaged in the upcoming discussions around the Pharmaceutical Strategy, including the legislation on medicines for special populations (Regulation on Orphan Medicinal Products and on Paediatrics)
- **3. Support rare diseases research** by ensuring adequate support to a successful Partnership like the European Joint Programme on Rare Diseases.



Other actions that need support



Organise a European Parliament (EP) event in the context of the RareImpact project that addresses the difficulties of patients accessing advanced therapies;



Promote and organise the final meeting of the Rare 2030 pilot project, promoted by the European Parliament and co-funded by the European Commission.



RARE DISEASE DAY®

Encourage patient organisations to participate in European policy-making by supporting 2021 Rare Disease Week, either by meeting your constituents during this week and/or organise a bigger meeting in the EP.





EURORDIS EXPERTISE

Our mission

EURORDIS works across borders and diseases to improve the lives of people living with a rare disease

Member patient organisations

71 countries (28 EU countries)

National Alliances of rare disease patient organisations

72 European Federations for

specific rare diseases

Staff members with offices in Paris, Brussels and Barcelona

Founded in




patient groups

Outreach to over

Over

volunteers



EURORDIS volunteers at the heart of policy making

volunteers involved in EURORDIS activities

Drug Information, Transparency and Access Task Force (DITA)

440

focusses on the areas of product information, transparency of the regulatory process and access to medicines



ePAG Advocates who are members of the EURORDIS **ePAG Steering Committee** active across 24 European Reference Networks



Rare Disease Day Working Group Co-creating the global campaign



HTA Task Force

to facilitate the participation of patients in health technology assessment activities



RareConnect moderators animate the RareConnect communities



SPAG (Social Policy Action Group) advocating for holistic & integrated care



Therapeutic Action Group (TAG), composed of EURORDIS volunteers in the scientific committees and working party at the **European Medicines Agency** (EMA)



HOW CAN YOU HELP CONCRETELY?



